These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 30194267)

  • 21. Activating PI3Kδ mutations in a cohort of 669 patients with primary immunodeficiency.
    Elgizouli M; Lowe DM; Speckmann C; Schubert D; Hülsdünker J; Eskandarian Z; Dudek A; Schmitt-Graeff A; Wanders J; Jørgensen SF; Fevang B; Salzer U; Nieters A; Burns S; Grimbacher B
    Clin Exp Immunol; 2016 Feb; 183(2):221-9. PubMed ID: 26437962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical, Immunological, and Genetic Features in Patients with Activated PI3Kδ Syndrome (APDS): a Systematic Review.
    Jamee M; Moniri S; Zaki-Dizaji M; Olbrich P; Yazdani R; Jadidi-Niaragh F; Aghamahdi F; Abolhassani H; Condliffe AM; Aghamohammadi A; Azizi G
    Clin Rev Allergy Immunol; 2020 Dec; 59(3):323-333. PubMed ID: 31111319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel germline gain-of-function variant in PIK3CD.
    Rae W; Gao Y; Ward D; Mattocks CJ; Eren E; Williams AP
    Clin Immunol; 2017 Aug; 181():29-31. PubMed ID: 28578023
    [No Abstract]   [Full Text] [Related]  

  • 24. The case of an APDS patient: Defects in maturation and function and decreased in vitro anti-mycobacterial activity in the myeloid compartment.
    Chiriaco M; Brigida I; Ariganello P; Di Cesare S; Di Matteo G; Taus F; Cittaro D; Lazarevic D; Scarselli A; Santilli V; Attardi E; Stupka E; Giannelli S; Fraziano M; Finocchi A; Rossi P; Aiuti A; Palma P; Cancrini C
    Clin Immunol; 2017 May; 178():20-28. PubMed ID: 26732860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical and genetic analysis for activated PI3K-δ syndrome by PIK3CD gene mutation].
    Liu H; Tang XL; Liu JR; Li HM; Zhao SY
    Zhonghua Er Ke Za Zhi; 2016 Sep; 54(9):698-702. PubMed ID: 27596086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. E1021K Homozygous Mutation in PIK3CD Leads to Activated PI3K-Delta Syndrome 1.
    Wang Y; Chen X; Yang Q; Tang W; Jia Y; Zhou L; An Y; Zhang Z; Tang X; Zhao X
    J Clin Immunol; 2020 Feb; 40(2):378-387. PubMed ID: 31953711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activated PI3K-delta syndrome in an Egyptian pediatric cohort with primary immune deficiency.
    Ahmed AA; El Shahaway AA; Hussien SA
    Allergol Immunopathol (Madr); 2020; 48(6):686-693. PubMed ID: 32349894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hyper-activated PI3K-δ in immunodeficiency.
    Heurtier L; Deau MC; Kracker S
    Oncotarget; 2015 Jul; 6(21):18242-3. PubMed ID: 26286043
    [No Abstract]   [Full Text] [Related]  

  • 29. The First Iranian Cohort of Pediatric Patients with Activated Phosphoinositide 3-Kinase-δ (PI3Kδ) Syndrome (APDS).
    Fekrvand S; Delavari S; Chavoshzadeh Z; Sherkat R; Mahdaviani SA; Sadeghi Shabestari M; Azizi G; Arzanian MT; Shahin Shamsian B; Eskandarzadeh S; Eslami N; Rae W; Condino-Neto A; Mohammadi J; Abolhassani H; Yazdani R; Aghamohammadi A
    Immunol Invest; 2022 Apr; 51(3):644-659. PubMed ID: 33401995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical and immunological analysis of patients with activated phosphoinositide 3-kinase δ syndrome resulting from PIK3CD mutation].
    Tang WJ; Wang W; Luo Y; Wang YP; Li L; An YF; Gou LJ; Ma MS; He TY; Yang J; Zhao XD; Song HM
    Zhonghua Er Ke Za Zhi; 2017 Jan; 55(1):19-24. PubMed ID: 28072954
    [No Abstract]   [Full Text] [Related]  

  • 31. Phosphatase and tensin homolog (PTEN) mutation can cause activated phosphatidylinositol 3-kinase δ syndrome-like immunodeficiency.
    Tsujita Y; Mitsui-Sekinaka K; Imai K; Yeh TW; Mitsuiki N; Asano T; Ohnishi H; Kato Z; Sekinaka Y; Zaha K; Kato T; Okano T; Takashima T; Kobayashi K; Kimura M; Kunitsu T; Maruo Y; Kanegane H; Takagi M; Yoshida K; Okuno Y; Muramatsu H; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Kojima S; Ogawa S; Ohara O; Okada S; Kobayashi M; Morio T; Nonoyama S
    J Allergy Clin Immunol; 2016 Dec; 138(6):1672-1680.e10. PubMed ID: 27426521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systematic review of mortality and survival rates for APDS.
    Hanson J; Bonnen PE
    Clin Exp Med; 2024 Jan; 24(1):17. PubMed ID: 38280023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Case Report: Activating
    Lu M; Gu W; Sheng Y; Wang J; Xu X
    Front Immunol; 2021; 12():670312. PubMed ID: 33995405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term follow-up of an activated PI3K-δ syndrome 2 in patient presenting with an agammaglobulinemia phenotype.
    Nguyen Y; Rosain J; Aguilar C; Picard C; Malphettes M
    Ann Allergy Asthma Immunol; 2018 Dec; 121(6):739-740.e1. PubMed ID: 30081089
    [No Abstract]   [Full Text] [Related]  

  • 35. Immunodeficiency due to a novel variant in PIK3CD: a case report.
    Shashaani N; Chavoshzadeh Z; Ghasemi L; Ghotbabadi SH; Shiari S; Sharafian S; Shiari R
    Pediatr Rheumatol Online J; 2023 Jul; 21(1):71. PubMed ID: 37475052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activated PI3Kδ breaches multiple B cell tolerance checkpoints and causes autoantibody production.
    Lau A; Avery DT; Jackson K; Lenthall H; Volpi S; Brigden H; Russell AJ; Bier J; Reed JH; Smart JM; Cole T; Choo S; Gray PE; Berglund LJ; Hsu P; Wong M; O'Sullivan M; Boztug K; Meyts I; Uzel G; Notarangelo LD; Brink R; Goodnow CC; Tangye SG; Deenick EK
    J Exp Med; 2020 Feb; 217(2):. PubMed ID: 31841125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulating the PI3K Signalling Pathway in Activated PI3K Delta Syndrome: a Clinical Perspective.
    Berglund LJ
    J Clin Immunol; 2023 Dec; 44(1):34. PubMed ID: 38148368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel monoallelic gain of function mutation in p110δ causing atypical activated phosphoinositide 3-kinase δ syndrome (APDS-1).
    Lougaris V; Baronio M; Moratto D; Tampella G; Gazzurelli L; Facchetti M; Martire B; Cardinale F; Lanzarotto F; Bondioni MP; Villanacci V; Grimbacher B; Plebani A
    Clin Immunol; 2019 Mar; 200():31-34. PubMed ID: 30639166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interim analysis: Open-label extension study of leniolisib for patients with APDS.
    Rao VK; Kulm E; Šedivá A; Plebani A; Schuetz C; Shcherbina A; Dalm VA; Trizzino A; Zharankova Y; Webster S; Orpia A; Körholz J; Lougaris V; Rodina Y; Radford K; Bradt J; Relan A; Holland SM; Lenardo MJ; Uzel G
    J Allergy Clin Immunol; 2024 Jan; 153(1):265-274.e9. PubMed ID: 37797893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gain of Function Mutations of PIK3CD as a Cause of Primary Sclerosing Cholangitis.
    Hartman HN; Niemela J; Hintermeyer MK; Garofalo M; Stoddard J; Verbsky JW; Rosenzweig SD; Routes JM
    J Clin Immunol; 2015 Jan; 35(1):11-4. PubMed ID: 25352054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.